{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-15228497-teriparatide:v1","objectPathId":"pubmed-pmid-15228497-teriparatide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-15228497-teriparatide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-15228497-teriparatide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-15228497-teriparatide-v1.md"},"story":{"slug":"pubmed-pmid-15228497-teriparatide","version":1,"domain":"Literature metadata","dateInSource":"2013-11-21","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["teriparatide"],"peptides":[{"slug":"teriparatide","url":"https://peptidescanner.com/peptides/teriparatide/"}]},"claims":[{"id":"headline","text":"Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.","sourceIds":["pubmed-observation-pmid-15228497-2013-11-21-b275f2532021"]},{"id":"summary","text":"PubMed lists PMID 15228497 in Basic & clinical pharmacology & toxicology as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-06 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-15228497-2013-11-21-b275f2532021"]},{"id":"paragraph-1","text":"PubMed lists PMID 15228497 in Basic & clinical pharmacology & toxicology as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-06 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-15228497-2013-11-21-b275f2532021"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-15228497-2013-11-21-b275f2532021"]}],"sources":[{"id":"pubmed-observation-pmid-15228497-2013-11-21-b275f2532021","name":"PubMed","sourceClass":"A","title":"Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. · retained source version 1:2013-11-21:current:b275f25320218cc5a24086db6b1a89e3a2a90793f8acea334fd2d8828f69a99a","url":"https://pubmed.ncbi.nlm.nih.gov/15228497/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"ed9201477429b4e93adaca4f1f8caf550537794be6f0bf6d6be74651ec93c566","tierARecordSha256":"60d86ad7a2a79bb882b511654de67fccbc3ea380e1f19eed3e6c04afcaf0601b"},"integrity":{"algorithm":"sha256","contentSha256":"8328de34d5e4a83edea0a787b9b799a227d583a67d05b04a84e7705444b30087"}}